Effect of saroglitazar 2Â mg and 4Â mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Krishnappa, Manjunath, Patil, Kishor, Parmar, Krupi, Trivedi, Purav, Mody, Nirali, Shah, Chintan, Faldu, Khushboo, Maroo, Sanjay, Parmar, DevenVolume:
19
Journal:
Cardiovascular Diabetology
DOI:
10.1186/s12933-020-01073-w
Date:
December, 2020
File:
PDF, 1.11 MB
2020